Advances in interleukin-10-based therapies for pulmonary diseases: focus on targeted lung delivery systems
Tian W., Wang X., Zeng J., Gao Y., Tang S., Ma C.
Clinical Trial on Chronic Inflammation, published in Front Immunol (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Front Immunol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41312367
- PMCID
- PMC12646918
- DOI
- 10.3389/fimmu.2025.1630990
- Citations
- 2
Abstract (original English)
Interleukin-10 (IL-10) is an anti-inflammatory cytokine that exerts diverse effects on immune regulation. It alleviates excessive inflammatory responses in the body by inhibiting the expression of pro-inflammatory cytokines and the activation of antigen-presenting cells. In recent years, the therapeutic potential of IL-10 in various pulmonary inflammatory diseases has attracted extensive attention, including acute lung injury (ALI), acute respiratory distress syndrome (ARDS), asthma, and pulmonary fibrosis. IL-10 has also been studied in lung transplantation to improve the pro-inflammatory cytokine profile of donor lungs that do not meet conventional criteria. Nonetheless, its limited bioavailability, short half-life and potential for systemic adverse effects constrain its clinical application. To enhance its therapeutic efficacy and lung tissue targeting, intranasal administration and nebulized inhalation are the earliest methods applied in pulmonary diseases. Recombinant proteins, engineered mesenchymal stem cells, nanoparticle delivery systems, and gel delivery systems have also been developed and are undergoing preclinical trials. Many drug delivery platforms and pulmonary-targeted approaches have been shown to effectively increase the drug's accumulation in the lungs and sustain its release, thus minimizing systemic toxicity. These IL-10-based therapies for pulmonary disea
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions
Systematic Review on Tendon Injury, Rotator Cuff, Shoulder Pain, Chronic Inflammation, published in J Orthop Sports Med (2026) — summary generated from the PubMed abstract.
- 2026
J Orthop Sports Med - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level AMeta-analysisPubMed
Comparative efficacy of different doses of mesenchymal stem cells derived from different tissue sources for knee osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials.
Meta-analysis with a reported sample of 602 on Knee Osteoarthritis, Osteoarthritis, Chronic Inflammation, Immune Modulation, published in PeerJ (2026) — summary generated from the PubMed abstract.
- 2026
- n = 602
PeerJ - Level ASystematic ReviewEurope PMC
Exosomes as Cellular Communicators and Therapeutic Agents in Orthopedic Diseases: From Mechanisms to Intervention
Systematic Review on Osteoarthritis, Chronic Inflammation, published in Int J Nanomedicine (2026) — summary generated from the PubMed abstract.
- 2026
Int J Nanomedicine1 citations - Level ASystematic ReviewEurope PMC
Pharmacotherapy agents in prevention and treatment of breast cancer-related lymphedema: a systematic scoping review
Systematic Review on Chronic Inflammation, Immune Modulation, published in Front Oncol (2026) — summary generated from the PubMed abstract.
- 2026
Front Oncol - Level ASystematic ReviewEurope PMC
Trends in peripheral nerve injury research: a bibliometric analysis focused on molecular mechanisms
Systematic Review on Chronic Inflammation, published in Front Neurol (2026) — summary generated from the PubMed abstract.
- 2026
Front Neurol